X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 10, 2021
Details:
The Company intends to use the net proceeds from this offering to fund the continued clinical development of elamipretide and for working capital and general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
DCN suggested that, based on the short half-life of elamipretide, a short-term withdrawal period could be sufficient to measure durable effect on functional or structural cardiac endpoints by demonstrating that improvement is not dependent on continuous exposure to the drug.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
